Senti Bio Collaborates with BlueRock to Develop Gene Circuit Engineered Cell Therapies for Regenerative Medicine
Shots:
- BlueRock to get an option to license gene circuits emerging from the collaboration for cell therapy products in specific indications. If option exercises- the company will be responsible for conducting pre/clinical and commercialization activities for any candidates incorporating Senti Bio’s licensed gene circuits
- Senti Bio will strengthen BlueRock’s cell+gene platform by developing gene circuits and will be responsible for designing and testing cell state- and disease- specific Smart Sensors and Regulator Dials to be utilized in regenerative therapies
- The collaboration combines BlueRock’s iPSC platform technology and expertise with Senti Bio’s gene circuit technology platform
Ref: Globe Newswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com